AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01080365
Drug: SKI-606 (Bosutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
Trial: NCT02379637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02339246
Drug: Prograf vs Astagraf XL vs Envarsus XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf vs Astagraf XL vs Envarsus XR
Trial: NCT04635956
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
Trial: NCT00823875
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine treatment
Trial: NCT03795272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06143904
Drug: Genz-112638
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution-Route of administration:IV
Trial: NCT06143904
Drug: Genz-112638
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Trial: NCT06143904
Drug: [14C]-Genz-112638
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution-Route of administration:Oral
Trial: NCT02510560
Drug: NTRA-2112
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02510560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00152919
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04466670
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Trial: NCT04466670
Drug: Unfractionated heparin nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Trial: NCT04681105
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04681105
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03304938
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Trial: NCT01798849
Drug: MK-8892
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01798849
Drug: Placebo for MK-8892
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03535298
Drug: Early Highly Effective Therapies Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly Effective MS Therapy group of medications
Trial: NCT03535298
Drug: Escalation Therapies Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation MS Therapy group of medications
Trial: NCT04279613
Drug: NNC0361-0041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
Trial: NCT02929407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
Trial: NCT03308721
Drug: NNC9204-1177 A 1.0 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg.
Trial: NCT03308721
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
Trial: NCT01160822
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT01160822
Drug: Placebo to Naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT03037580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill) for TID oral administration
Trial: NCT00152269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Tablet, oral Daily for 12 months
Trial: NCT00648960
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 500 mg immediate-release oral tablet
Trial: NCT00648960
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 500 mg immediate-release oral dose
Trial: NCT00268853
Drug: CPOP-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Trial: NCT00268853
Drug: CHOP-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
Trial: NCT00614705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule form, once daily for 28 days
Trial: NCT04448756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo tablets matched to M5049 daily for 14 days.
Trial: NCT00794443
Drug: YM529 / ONO-5920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01479829
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug
Trial: NCT01479829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a manufactured capsule with no active ingredient
Trial: NCT04541771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
Trial: NCT00740857
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo gels capsules delivered as a single dose.
Trial: NCT00740857
Drug: ibuprofen Formulation 1
RxNorm normalized name: ibuprofen 0.1 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 marketed ibuprofen gels
Trial: NCT00740857
Drug: ibuprofen Formulation 2
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 marketed ibuprofen gels
Trial: NCT00217178
Drug: Vitamins: Folic acid, B6, B12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02527421
Drug: DFD01 Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Trial: NCT00790270
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg every 8 hours as needed
Trial: NCT00790270
Drug: Ibuprofen plus Cyclobenzaprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
Trial: NCT00282308
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01584440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT01237899
Drug: LY2623091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01237899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01237899
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00576329
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical use before surgery
Trial: NCT00337675
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
Trial: NCT00065169
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02036970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01871740
Drug: Enalapril maleate and folic acid tablets
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Trial: NCT02350478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive placebo orally once daily for 12 weeks.
Trial: NCT00846963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
Trial: NCT00218218
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00771953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
Trial: NCT01254708
Drug: Ambisome ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal amphotericin B
Trial: NCT01254708
Drug: Regular standard of care medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
Trial: NCT01086358
Drug: Triptan
RxNorm normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
Trial: NCT01086358
Drug: Treximet 85Mg-500Mg Tablet
RxNorm normalized name: Treximet 85mg-500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
Trial: NCT00578292
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per institutional guidelines Days -5 through -2
Trial: NCT00578292
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg Days -5 through -2
Trial: NCT04044937
Drug: F-18 Fluoroethyltyrosine (FET)
RxNorm normalized name: FET F-18
DrugBank: FET F-18 (DB15405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
Trial: NCT01924949
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
Trial: NCT02614599
Drug: BP22042013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Trial: NCT01302249
Drug: AR-12286 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162019
Drug: Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006205
Drug: Placebo + cognitive behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02615639
Drug: HPDC-T cells & IFN-a-2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
Trial: NCT01262989
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Trial: NCT01262989
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0,4 mg (Boehringer Ingelheim)
Trial: NCT04380519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Trial: NCT03005899
Drug: SyB P-1501
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed
Trial: NCT03005899
Drug: SyB P-1501 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
Trial: NCT00635219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules; daily; orally
Trial: NCT00244543
Drug: R89674 (generic name not yet established)
RxNorm normalized name: forget-me-not extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04349800
Drug: KVD900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT04349800
Drug: Placebo to KVD900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00262626
Drug: Intraocular pressure reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01191762
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets with each meal
Trial: NCT03331640
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
Trial: NCT00397917
Drug: Folic acid: 4 mg versus 0.4 mg per day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid
Trial: NCT01617746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bd for two weeks
Trial: NCT03144934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo of GX-I7 described above.
Trial: NCT01783691
Drug: NKTT120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02543060
Drug: cavity protection toothpaste
RxNorm normalized name: Aquafresh Cavity Protection Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.243% sodium fluoride toothpaste
Trial: NCT00482664
Drug: CP-866,087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT00482664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT00409357
Drug: SL77.0499-10 (alfuzosin hydrochloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01934777
Drug: Docosahexaenoic Acid plus Vitamin E plus choline
RxNorm normalized name: cholecalciferol / docosahexaenoic acid / eicosapentaenoic acid / vitamin E Oral Capsule [Sea-Omega Plus D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
Trial: NCT00524901
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
Trial: NCT03682211
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
Trial: NCT01519167
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 - 3 mcg/kg IV
Trial: NCT02452515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
Trial: NCT00543530
Drug: MK0831
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02657785
Drug: R-IDARAM plus intrathecal chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Trial: NCT01955629
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Tablets; Route of administration: Oral
Trial: NCT02562664
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken twice daily continuously for three cycles.
Trial: NCT02633696
Drug: silybin phosphatidylcholine
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02633696
Drug: Legalón SIL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00351871
Drug: PEG-Intron Plus REBETOL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00571168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules on day 1-4
Trial: NCT02659397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
Trial: NCT02613026
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01415336
Drug: Doxorubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
Trial: NCT01415336
Drug: doxorubicin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
Trial: NCT03323567
Drug: MD Muscle GUNA collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramusclular injections of MD Muscle collagen
Trial: NCT03323567
Drug: Saline Solution, Hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular Saline injection
Trial: NCT02940314
Drug: HIP1503
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02940314
Drug: HGP1103
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00504972
Drug: hLL1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
Trial: NCT01526707
Drug: inhaled steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled budesonide for 7 days
Trial: NCT00137891
Drug: Modified Release rhTSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02884713
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Trial: NCT04079140
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.